WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received [...] Read more »
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical–stage oncology company, today announced the closing of its merger with Biosight, [...] Read more »
Gap Inc., Cargill, and GSK Join the Water Resilience Coalition and WaterAid to Improve Access to Water in India as Part of the Coalition's 2030 100-Basin Plan
New York, New York, Oct. 17, 2023 (GLOBE NEWSWIRE) — The Water Resilience Coalition (WRC), an industry–driven, CEO–led initiative convening global companies to address the global water crisis, today announced the launch [...] Read more »
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting
JERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, presented [...] Read more »
Une nouvelle étude mondiale révèle que les personnes qui souffrent se sentent plus socialement exclues que jamais
Une nouvelle tude mondiale rvle que les personnes qui souffrent se sentent plus socialement exclues que jamais
- La toute dernire dition de [...] Read more »
Novo estudo global revela que pessoas que sentem dor estão se sentindo cada vez mais socialmente excluídas
- ltima edio do ndice de Dor Haleon revela que metade (49%) das pessoas com dor se sentem estigmatizadas[1][2]
- Read more »
Neue globale Studie zeigt, dass Menschen mit Schmerzen sich mehr denn je sozial ausgegrenzt fühlen
- Laut der neuesten Ausgabe des Haleon Pain Index fhlt sich die Hlfte (49 %) der Menschen mit Schmerzen [...] Read more »
Les spécialistes du rein en Tunisie recommandent l'utilisation des solutions QuantiFERON de QIAGEN
TUNIS, Tunisie, 28 sept. 2023 (GLOBE NEWSWIRE) — QIAGEN annonce que l'utilisation de ses tests de la gamme QuantiFERON a t recommande par les cliniciens de la Socit Tunisienne de Nphrologie pour la prise en charge des patients [...] Read more »
QIAGEN’s QuantiFERON solutions recommended for use by kidney specialists in Tunisia
- Tunisian Society of Nephrology first professional body in the field to publish nationwide guidance
- Association of specialists [...] Read more »
New global study discovers people in pain feel more socially excluded than ever
- Latest edition of Haleon Pain Index finds half (49%) of people in pain feel [...] Read more »
Impulse Dynamics Announces Leadership Changes
MARLTON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership appointments, including Jason Spees to [...] Read more »
Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa
WEST LAFAYETTE, Ind., Sept. 15, 2023 (GLOBE NEWSWIRE) — A Purdue researcher is taking a giant leap forward in the fight against drug–resistant strains of malaria in developing countries.
Conagen innovates novel natural-source retinol for cosmetic formulations
Bedford, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) — Read more »
Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology
Estudo revelou que o obexelimabe produziu melhora clnica rpida, forte e sustentada, incluindo remisso clnica completa, na maioria dos pacientes com IgG4–RD ativa
Os resultados apoiam o [...] Read more »
Zenas BioPharma gibt die Veröffentlichung von Daten zu einer Phase-2-Studie mit Obexelimab, einem Prüfpräparat zur Behandlung der IgG4-assoziierten Erkrankung (IgG4-RD), im Fachjournal „The Lancet Rheumatology“ bekannt
Die Studie ergab, dass Obexelimab bei den meisten Patientinnen und Patienten mit aktiver IgG4–RD zu einer schnellen, deutlichen und anhaltenden klinischen Verbesserung, einschlielich einer vollstndigen klinischen [...] Read more »